FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294025552> ?p ?o ?g. }

• W4294025552 endingPage "1394" @default.
• W4294025552 startingPage "1390" @default.
• W4294025552 abstract "Objective Immunoglobulin A vasculitis (IgAV) usually occurs following viral respiratory tract infection. In the context of the global coronavirus disease 2019 (COVID-19) pandemic, we describe a case series of patients who developed IgAV following SARS-CoV-2 infection. Methods This national multicenter retrospective study included patients with IgAV following SARS-CoV-2 infection from January 1, 2020, to January 1, 2022. Patients had histologically proven IgAV and reverse transcription PCR (RT-PCR)-proven SARS-CoV-2 infection. The interval between infection and vasculitis onset had to be < 4 weeks. Results We included 5 patients, 4 of whom were women with a mean age of 45 years. Four patients had paucisymptomatic infections and 1 required a 48-hour low-flow oxygen treatment. All 5 patients had purpuric skin involvement. Arthritis was observed in 2 patients, 3 had IgA glomerulonephritis, and 2 had digestive involvement. Three renal biopsies were performed and showed mesangial IgA deposits without any extracapillary proliferation. Median C-reactive protein was 180 (range 15.1-225) mg/L, median serum creatinine level was 65 (range 41-169) µmol/L, and 2 patients had a glomerular filtration rate < 60 mL/min. Four patients received first-line treatment with glucocorticoids. All patients had a favorable progression and 2 patients experienced minor skin relapses, one after COVID-19 vaccination. Conclusion This series describes the emergence of IgAV closely following COVID-19; we were not able to eliminate an incidental link between these events. Their disease outcomes were favorable. In most of our patients, the SARS-CoV-2 infection was paucisymptomatic, and we recommend RT-PCR tests to look for COVID-19 in patients without any evident triggers for IgAV." @default.
• W4294025552 created "2022-09-01" @default.
• W4294025552 creator A5003360902 @default.
• W4294025552 creator A5028093101 @default.
• W4294025552 creator A5028732857 @default.
• W4294025552 creator A5040136784 @default.
• W4294025552 creator A5040714271 @default.
• W4294025552 creator A5047449259 @default.
• W4294025552 creator A5048188689 @default.
• W4294025552 creator A5059781332 @default.
• W4294025552 creator A5067247281 @default.
• W4294025552 creator A5071681341 @default.
• W4294025552 creator A5079144534 @default.
• W4294025552 creator A5090001534 @default.
• W4294025552 creator A5091324557 @default.
• W4294025552 creator A5091573480 @default.
• W4294025552 date "2022-09-01" @default.
• W4294025552 modified "2023-10-16" @default.
• W4294025552 title "Immunoglobulin A Vasculitis Following COVID-19: A French Multicenter Case Series" @default.
• W4294025552 cites W2017538892 @default.
• W4294025552 cites W2031517139 @default.
• W4294025552 cites W2151704308 @default.
• W4294025552 cites W2427686478 @default.
• W4294025552 cites W2763037910 @default.
• W4294025552 cites W2952342852 @default.
• W4294025552 cites W3027918021 @default.
• W4294025552 cites W3038214791 @default.
• W4294025552 cites W3049228724 @default.
• W4294025552 cites W3069630252 @default.
• W4294025552 cites W3107851654 @default.
• W4294025552 cites W3111555681 @default.
• W4294025552 cites W3171779092 @default.
• W4294025552 cites W3191293633 @default.
• W4294025552 cites W3208248750 @default.
• W4294025552 cites W3216843202 @default.
• W4294025552 cites W3217556094 @default.
• W4294025552 cites W4235122015 @default.
• W4294025552 cites W4280573022 @default.
• W4294025552 doi "https://doi.org/10.3899/jrheum.220503" @default.
• W4294025552 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36243405" @default.
• W4294025552 hasPublicationYear "2022" @default.
• W4294025552 type Work @default.
• W4294025552 citedByCount "4" @default.
• W4294025552 countsByYear W42940255522023 @default.
• W4294025552 crossrefType "journal-article" @default.
• W4294025552 hasAuthorship W4294025552A5003360902 @default.
• W4294025552 hasAuthorship W4294025552A5028093101 @default.
• W4294025552 hasAuthorship W4294025552A5028732857 @default.
• W4294025552 hasAuthorship W4294025552A5040136784 @default.
• W4294025552 hasAuthorship W4294025552A5040714271 @default.
• W4294025552 hasAuthorship W4294025552A5047449259 @default.
• W4294025552 hasAuthorship W4294025552A5048188689 @default.
• W4294025552 hasAuthorship W4294025552A5059781332 @default.
• W4294025552 hasAuthorship W4294025552A5067247281 @default.
• W4294025552 hasAuthorship W4294025552A5071681341 @default.
• W4294025552 hasAuthorship W4294025552A5079144534 @default.
• W4294025552 hasAuthorship W4294025552A5090001534 @default.
• W4294025552 hasAuthorship W4294025552A5091324557 @default.
• W4294025552 hasAuthorship W4294025552A5091573480 @default.
• W4294025552 hasBestOaLocation W42940255521 @default.
• W4294025552 hasConcept C126322002 @default.
• W4294025552 hasConcept C151730666 @default.
• W4294025552 hasConcept C159654299 @default.
• W4294025552 hasConcept C203014093 @default.
• W4294025552 hasConcept C2776015282 @default.
• W4294025552 hasConcept C2776553844 @default.
• W4294025552 hasConcept C2779102806 @default.
• W4294025552 hasConcept C2779134260 @default.
• W4294025552 hasConcept C2779343474 @default.
• W4294025552 hasConcept C2780091579 @default.
• W4294025552 hasConcept C2780306776 @default.
• W4294025552 hasConcept C2780368995 @default.
• W4294025552 hasConcept C2780898057 @default.
• W4294025552 hasConcept C71924100 @default.
• W4294025552 hasConcept C86803240 @default.
• W4294025552 hasConcept C90924648 @default.
• W4294025552 hasConceptScore W4294025552C126322002 @default.
• W4294025552 hasConceptScore W4294025552C151730666 @default.
• W4294025552 hasConceptScore W4294025552C159654299 @default.
• W4294025552 hasConceptScore W4294025552C203014093 @default.
• W4294025552 hasConceptScore W4294025552C2776015282 @default.
• W4294025552 hasConceptScore W4294025552C2776553844 @default.
• W4294025552 hasConceptScore W4294025552C2779102806 @default.
• W4294025552 hasConceptScore W4294025552C2779134260 @default.
• W4294025552 hasConceptScore W4294025552C2779343474 @default.
• W4294025552 hasConceptScore W4294025552C2780091579 @default.
• W4294025552 hasConceptScore W4294025552C2780306776 @default.
• W4294025552 hasConceptScore W4294025552C2780368995 @default.
• W4294025552 hasConceptScore W4294025552C2780898057 @default.
• W4294025552 hasConceptScore W4294025552C71924100 @default.
• W4294025552 hasConceptScore W4294025552C86803240 @default.
• W4294025552 hasConceptScore W4294025552C90924648 @default.
• W4294025552 hasIssue "12" @default.
• W4294025552 hasLocation W42940255521 @default.
• W4294025552 hasLocation W42940255522 @default.
• W4294025552 hasOpenAccess W4294025552 @default.
• W4294025552 hasPrimaryLocation W42940255521 @default.
• W4294025552 hasRelatedWork W142717363 @default.

• next